ORIC Pharmaceuticals - ORIC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $20.00
  • Forecasted Upside: 187.77%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$6.95
▼ -0.28 (-3.87%)

This chart shows the closing price for ORIC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ORIC Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ORIC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ORIC

Analyst Price Target is $20.00
▲ +187.77% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for ORIC Pharmaceuticals in the last 3 months. The average price target is $20.00, with a high forecast of $27.00 and a low forecast of $14.00. The average price target represents a 187.77% upside from the last price of $6.95.

This chart shows the closing price for ORIC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in ORIC Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/27/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/20/2024Cantor FitzgeraldReiterated RatingOverweightLow
5/28/2024Cantor FitzgeraldReiterated RatingOverweightLow
5/7/2024CitigroupLower TargetBuy ➝ Buy$15.00 ➝ $14.00Low
3/27/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$19.00 ➝ $18.00Low
3/21/2024HC WainwrightBoost TargetBuy ➝ Buy$15.00 ➝ $21.00Low
3/1/2024WedbushBoost TargetOutperform ➝ Outperform$12.00 ➝ $20.00Low
2/23/2024Cantor FitzgeraldInitiated CoverageOverweightLow
1/8/2024WedbushReiterated RatingOutperform$12.00Low
12/13/2023HC WainwrightLower TargetBuy ➝ Buy$16.00 ➝ $15.00Low
10/26/2023HC WainwrightBoost TargetBuy ➝ Buy$13.00 ➝ $16.00Low
10/23/2023WedbushReiterated RatingOutperform ➝ Outperform$14.00Low
9/21/2023WedbushInitiated CoverageOutperform$8.00Low
9/5/2023CitigroupBoost Target$8.00 ➝ $13.00Low
8/16/2023Robert W. BairdBoost TargetOutperform ➝ Outperform$15.00 ➝ $27.00Low
8/15/2023HC WainwrightLower TargetBuy ➝ Buy$14.00 ➝ $13.00Low
5/10/2023HC WainwrightLower Target$16.00 ➝ $14.00Low
4/5/2023CitigroupLower TargetBuy$9.00 ➝ $8.00Low
3/23/2023HC WainwrightUpgradeNeutral ➝ Buy$16.00Low
3/21/2023JPMorgan Chase & Co.Lower TargetOverweight$16.00 ➝ $15.00Low
3/21/2023GuggenheimUpgradeNeutral ➝ Buy$15.00Low
3/16/2023OppenheimerUpgradeMarket Perform ➝ Outperform$14.00Low
7/15/2022OppenheimerInitiated CoverageHoldLow
5/20/2022CitigroupLower TargetBuy$9.00Low
4/4/2022CitigroupUpgradeNeutral ➝ Buy$7.00 ➝ $10.00High
3/25/2022HC WainwrightDowngradeBuy ➝ NeutralMedium
3/22/2022GuggenheimDowngradeBuy ➝ NeutralHigh
3/22/2022CitigroupDowngradeBuy ➝ Neutral$22.00 ➝ $7.00High
3/22/2022OppenheimerDowngradeOutperform ➝ Market PerformHigh
11/10/2021HC WainwrightBoost TargetBuy$30.00 ➝ $31.00Medium
10/8/2021Robert W. BairdLower TargetOutperform$47.00 ➝ $26.00High
10/8/2021CitigroupLower TargetBuy$33.00 ➝ $22.00High
10/8/2021HC WainwrightReiterated RatingBuy$53.00 ➝ $30.00High
9/23/2021HC WainwrightReiterated RatingBuy$53.00Low
8/11/2021HC WainwrightLower TargetBuy$54.00 ➝ $53.00High
7/6/2021CitigroupUpgradeNeutral ➝ BuyHigh
6/29/2021HC WainwrightReiterated RatingBuy$54.00High
6/6/2021Robert W. BairdReiterated RatingBuy$45.00High
3/25/2021HC WainwrightBoost TargetBuy$52.00 ➝ $54.00Low
1/25/2021CitigroupDowngradeBuy ➝ Neutral$34.00Low
11/9/2020HC WainwrightReiterated RatingBuyLow
8/12/2020Robert W. BairdInitiated CoverageOutperform$45.00Low
8/6/2020CitigroupUpgradeNeutral ➝ Buy$35.00High
8/3/2020HC WainwrightInitiated CoverageBuy$52.00High
6/19/2020OppenheimerReiterated RatingBuy$48.00High
6/11/2020OppenheimerInitiated CoverageMarket Perform$48.00High
5/19/2020JPMorgan Chase & Co.Initiated CoverageOverweight$40.00Low
5/19/2020Jefferies Financial GroupInitiated CoverageBuy$40.00Low
5/19/2020CitigroupInitiated CoverageNeutral$35.00Low
5/19/2020GuggenheimInitiated CoverageBuy$45.00Low
(Data available from 6/24/2019 forward)

News Sentiment Rating

0.19 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/27/2023
  • 7 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2023
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2024
  • 3 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/25/2024
  • 10 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/26/2024
  • 1 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/25/2024
  • 6 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/25/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/24/2024

Current Sentiment

  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
ORIC Pharmaceuticals logo
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $6.95
Low: $6.95
High: $7.38

50 Day Range

MA: $8.71
Low: $7.01
High: $9.76

52 Week Range

Now: $6.95
Low: $5.27
High: $16.65

Volume

127,343 shs

Average Volume

504,474 shs

Market Capitalization

$468.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

Frequently Asked Questions

What sell-side analysts currently cover shares of ORIC Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on ORIC Pharmaceuticals in the last twelve months: Cantor Fitzgerald, Citigroup Inc., HC Wainwright, JPMorgan Chase & Co., Robert W. Baird, and Wedbush.
View the latest analyst ratings for ORIC.

What is the current price target for ORIC Pharmaceuticals?

5 Wall Street analysts have set twelve-month price targets for ORIC Pharmaceuticals in the last year. Their average twelve-month price target is $20.00, suggesting a possible upside of 187.8%. Robert W. Baird has the highest price target set, predicting ORIC will reach $27.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $14.00 for ORIC Pharmaceuticals in the next year.
View the latest price targets for ORIC.

What is the current consensus analyst rating for ORIC Pharmaceuticals?

ORIC Pharmaceuticals currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ORIC will outperform the market and that investors should add to their positions of ORIC Pharmaceuticals.
View the latest ratings for ORIC.

What other companies compete with ORIC Pharmaceuticals?

How do I contact ORIC Pharmaceuticals' investor relations team?

ORIC Pharmaceuticals' physical mailing address is 240 E. GRAND AVE. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is 650-388-5600 and its investor relations email address is [email protected]. The official website for ORIC Pharmaceuticals is www.oricpharma.com. Learn More about contacing ORIC Pharmaceuticals investor relations.